Screening methods using G-protein coupled receptors and related compositions
The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.
1. A polypeptide of the formula PTH(1-X)/PTHrP(Y-36), or a pharmaceutically acceptable salt thereof, wherein X is an integer between 11 and 18 and Y is X+1, wherein said PTH(1-X) represents the amino acids 1 to X of the human PTH sequence (SEQ ID NO:5) and said PTHrP(Y-36) represents amino acids Y to 36 of the human PTHrP sequence (SEQ ID NO:6), wherein said polypeptide has a high affinity for the R° form of the PTH receptor, and wherein one or more of the following mutations are present in said polypeptide: Ala at position 1; Ala or Aib at position 3; Gln at position 10; Arg or homoarginine at position 11; Ala at position 12; and Trp at position 14.
2. The polypeptide of claim 1 , wherein said polypeptide has Ala at positions 1 and 12; Ala or Aib at position 3; Gln at position 10; Arg or homoarginine at position 11; Trp at position 14; and Arg at position 19.
3. The polypeptide of claim 2 , wherein said polypeptide has Ala at positions 1, 3 and 12; Gln at position 10; Arg at positions 11 and 19; and Trp at position 14.
4. The polypeptide of claim 1 , wherein said polypeptide is Mc-PTH(1-18)/PTHrP(19-36) (SEQ ID NO:16).
5. The polypeptide of claim 1 , wherein said polypeptide is Mc-PTH(1-14)/PTHrP(15-36) (SEQ ID NO:15).
6. The polypeptide of claim 1 , wherein said polypeptide is Mc-PTH(1-17)/PTHrP(18-36) (SEQ ID NO:139).
7. The polypeptide of claim 1 , wherein said polypeptide is Mc-PTH(1-11)/PTHrP(12-36) (SEQ ID NO:14).
8. The polypeptide of claim 1 , wherein said polypeptide has a hydroxyl group or is amidated at its C-terminus.
9. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.